pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2023-33-4-525-532pulmo-4321Research ArticleЛЕКЦИИLECTIONSМеханизмы развития легочной гипертензии при COVID-19Mechanisms of pulmonary hypertension development in COVID-19https://orcid.org/0000-0001-9357-4924ЦареваН. А.TsarevaN. A.

Царева Наталья Анатольевна — кандидат медицинских наук, доцент кафедры пульмонологии Института клинической медицины имени Н.В. Склифосовского.

119048, Москва, ул. Трубецкая, 8, стр. 2

тел.: (495) 609-14-00

Natal'ya A. Tsareva - Candidate of Medicine, Associate Professor, Department of Pulmonology, N.V. Sklifosovsky Institute of Clinical Medicine, Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University).

Trubetskaya ul. 8, build. 2, Moscow, 119048

tel.: (495) 609-14-00

n_tsareva@mail.ruФедеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian Federation202327062023334525532Copyright © Царева Н.А., 20232023Царева Н.А.Tsareva N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/4321

Новая коронавирусная инфекция (НКИ), вызванная SARS-CoV-2 (Severe Acute Respiratory Syndrome-relate CoronaVirus 2), представляет собой серьезное заболевание, часто связанное с сердечно-сосудистыми осложнениями. Сочетание острого респираторного дистресс-синдрома, инвазивной вентиляции легких, тромбоэмболических осложнений, а также прямого повреждения миокарда создает условия, при которых вероятно развитие дисфункции правого желудочка (ПЖ) вследствие легочной гипертензии (ЛГ). Целью работы явился поиск литературных источников в базах данных PubMed, Google Scholar и eLibrary и последующий их анализ для выяснения основных патофизиологических механизмов, которые играют роль в возникновении и прогрессировании ЛГ при COVID-19 (COronaVIrus Disease 2019). Повреждение вирусом миокарда, а также эндотелия легочных сосудов у госпитализированных пациентов с COVID-19 может способствовать развитию ЛГ, связанной с признаками более тяжелого течения заболевания и развитием недостаточности ПЖ в дальнейшем. Результаты. Установлено, что рутинный протокол эхокардиографического исследования следует расширить дополнительными показателями, которые свидетельствовали бы о функции ПЖ, поскольку эти данные могут применяться в качестве прогностического фактора риска. Заключение. По результатам анализа данных литературы показано, что НКИ в ряде случаев может приводить к развитию клинически значимой ЛГ.

The novel coronavirus infection caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome-relate CoronaVirus 2) is a serious disease often associated with cardiovascular complications. The combination of acute respiratory distress syndrome, invasive ventilation, thromboembolic complications, and direct myocardial injury creates conditions that increase likelihood of right ventricular (RV) dysfunction due to pulmonary hypertension (PH). The aim of the work was to search for literature sources in the PubMed, Google Scholar and eLibrary databases and analyze these sources to elucidate the main pathophysiological mechanisms that underly the onset and progression of PH in COVID-19 (COronaVIrus Disease 2019). Viral damage to the myocardium and pulmonary vascular endothelium in hospitalized patients with COVID-19 may contribute to the development of PH, which is associated with signs of a more severe course of the disease and the development of RV failure in the future. Results. It was concluded that the routine echocardiography protocol should be expanded with additional indicators of the right ventricular function, since these data can be used can be used to predict course of the disease. Conclusion. Based on the literature data, COVID-19 can lead to the development of clinically significant PH in some cases.

COVID-19легочная гипертензиядисфункция правого желудочкаэндотелиальная дисфункциявирус SARS-CoV-2COVID-19pulmonary hypertensionright ventricular dysfunctionendothelial dysfunctionSARS-CoV-2 virusПубликация осуществлена при поддержке Группы компаний «Фармасинтез».This publication has been produced with the support of JSC Pharmasyntez.ReferencesHumbert M., Kovacs G., Hoeper M.M. et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2022; 43 (38): 3618–3731. DOI: 10.1093/eurheartj/ehac237.Humbert M., Kovacs G., Hoeper M.M. et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2022; 43 (38): 3618–3731. DOI: 10.1093/eurheartj/ehac237.Кобелев Е., Берген Т.А., Таркова А.Р. и др. COVID-19 как причина хронической легочной гипертензии: патофизиологическое обоснование и возможности инструментальной диагностики. Кардиоваскулярная терапия и профилактика. 2021; 20 (5): 2844. DOI: 10.15829/1728-8800-2021-2844.Kobelev E., Bergen T.A., Tarkova A.R. et al. [COVID-19 as a cause of chronic pulmonary hypertension: pathophysiological rationale and potential of instrumental investigations]. Kardiovaskulyarnaya terapiya i profilaktika. 2021; 20 (5): 2844. DOI: 10.15829/1728-8800-2021-2844 (in Russian).Halawa S., Pullamsetti S.S., Bangham C.R.M. et al. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Nat. Rev. Cardiol. 2022; 19 (5): 314–331. DOI: 10.1038/s41569-021-00640-2.Halawa S., Pullamsetti S.S., Bangham C.R.M. et al. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Nat. Rev. Cardiol. 2022; 19 (5): 314–331. DOI: 10.1038/s41569-021-00640-2.Bernstein K.E., Khan Z., Giani J.F. et al. Angiotensin-converting enzyme in innate and adaptive immunity. Nat. Rev. Nephrol. 2018; 14 (5): 325–336. DOI: 10.1038/nrneph.2018.15.Bernstein K.E., Khan Z., Giani J.F. et al. Angiotensin-converting enzyme in innate and adaptive immunity. Nat. Rev. Nephrol. 2018; 14 (5): 325–336. DOI: 10.1038/nrneph.2018.15.Regev T., Antebi M., Eytan D. et al. Pediatric inflammatory multisystem syndrome with central nervous system involvement and hypocomplementemia following SARS-CoV-2 infection. Pediatr. Infect. Dis. J. 2020; 39 (8): e206–207. DOI: 10.1097/INF.0000000000002804.Regev T., Antebi M., Eytan D. et al. Pediatric inflammatory multisystem syndrome with central nervous system involvement and hypocomplementemia following SARS-CoV-2 infection. Pediatr. Infect. Dis. J. 2020; 39 (8): e206–207. DOI: 10.1097/INF.0000000000002804.Ouldali N., Pouletty M., Mariani P. et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the french COVID-19 epidemic: a time-series analysis. Lancet Child Adolesc. Health. 2020; 4 (9): 662–668. DOI: 10.1016/S2352-4642(20)30175-9.Ouldali N., Pouletty M., Mariani P. et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the french COVID-19 epidemic: a time-series analysis. Lancet Child Adolesc. Health. 2020; 4 (9): 662–668. DOI: 10.1016/S2352-4642(20)30175-9.Becker R.C. COVID-19-associated vasculitis and vasculopathy. J. Thromb. Thrombolysis. 2020; 50 (3): 499–511. DOI: 10.1007/s11239-020-02230-4.Becker R.C. COVID-19-associated vasculitis and vasculopathy. J. Thromb. Thrombolysis. 2020; 50 (3): 499–511. DOI: 10.1007/s11239-020-02230-4.Jin Y., Ji W., Yang H. et al. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct. Target. Ther. 2020; 5 (1): 293. DOI: 10.1038/s41392-020-00454-7.Jin Y., Ji W., Yang H. et al. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct. Target. Ther. 2020; 5 (1): 293. DOI: 10.1038/s41392-020-00454-7.Iba T., Levy J.H., Connors J.M. et al. The unique characteristics of COVID-19 coagulopathy. Crit. Care. 2020; 24 (1): 360. DOI: 10.1186/s13054-020-03077-0.Iba T., Levy J.H., Connors J.M. et al. The unique characteristics of COVID-19 coagulopathy. Crit. Care. 2020; 24 (1): 360. DOI: 10.1186/s13054-020-03077-0.Chan N.C., Weitz J.I. COVID-19 coagulopathy, thrombosis, and bleeding. Blood. 2020; 136 (4): 381–383. DOI: 10.1182/blood.2020007335.Chan N.C., Weitz J.I. COVID-19 coagulopathy, thrombosis, and bleeding. Blood. 2020; 136 (4): 381–383. DOI: 10.1182/blood.2020007335.Nägele M.P., Haubner B., Tanner F.C. et al. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis. 2020; 314: 58–62. DOI: 10.1016/j.atherosclerosis.2020.10.014.Nägele M.P., Haubner B., Tanner F.C. et al. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis. 2020; 314: 58–62. DOI: 10.1016/j.atherosclerosis.2020.10.014.Pennathur S., Heinecke J.W. Oxidative stress and endothelial dysfunction in vascular disease. Curr. Diab. Rep. 2007; 7 (4): 257–264. DOI: 10.1007/s11892-007-0041-3.Pennathur S., Heinecke J.W. Oxidative stress and endothelial dysfunction in vascular disease. Curr. Diab. Rep. 2007; 7 (4): 257–264. DOI: 10.1007/s11892-007-0041-3.Green S.J. COVID-19 accelerates endothelial dysfunction and nitric oxide deficiency. Microbes Infect. 2020; 22 (4-5): 149–150. DOI: 10.1016/j.micinf.2020.05.006.Green S.J. COVID-19 accelerates endothelial dysfunction and nitric oxide deficiency. Microbes Infect. 2020; 22 (4-5): 149–150. DOI: 10.1016/j.micinf.2020.05.006.Vabret N., Britton G.J., Gruber C. et al. Immunology of COVID-19: current state of the science. Immunity. 2020; 52 (6): 910–941. DOI: 10.1016/j.immuni.2020.05.002.Vabret N., Britton G.J., Gruber C. et al. Immunology of COVID-19: current state of the science. Immunity. 2020; 52 (6): 910–941. DOI: 10.1016/j.immuni.2020.05.002.Di A., Mehta D., Malik A.B. ROS-activated calcium signaling mechanisms regulating endothelial barrier function. Cell Calcium. 2016; 60 (3): 163–171. DOI: 10.1016/j.ceca.2016.02.002.Di A., Mehta D., Malik A.B. ROS-activated calcium signaling mechanisms regulating endothelial barrier function. Cell Calcium. 2016; 60 (3): 163–171. DOI: 10.1016/j.ceca.2016.02.002.Scioli M.G., Storti G., D'Amico F. et al. Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: potential diagnostic biomarkers and therapeutic targets. J. Clin. Med. 2020; 9 (6): 1995. DOI: 10.3390/jcm9061995.Scioli M.G., Storti G., D'Amico F. et al. Oxidative stress and new pathogenetic mechanisms in endothelial dysfunction: potential diagnostic biomarkers and therapeutic targets. J. Clin. Med. 2020; 9 (6): 1995. DOI: 10.3390/jcm9061995.Violi F., Oliva A., Cangemi R. et al. NOX2 activation in COVID-19. Redox Biol. 2020; 36: 101655. DOI: 10.1016/j.redox.2020.101655.Violi F., Oliva A., Cangemi R. et al. NOX2 activation in COVID-19. Redox Biol. 2020; 36: 101655. DOI: 10.1016/j.redox.2020.101655.Poyiadji N., Cormier P., Patel P.Y. et al. Acute pulmonary embolism and COVID-19. Radiology. 2020; 297 (3): E335–338. DOI: 10.1148/ radiol.2020201955.Poyiadji N., Cormier P., Patel P.Y. et al. Acute pulmonary embolism and COVID-19. Radiology. 2020; 297 (3): E335–338. DOI: 10.1148/ radiol.2020201955.Grillet F., Behr J., Calame P. et al. Acute pulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography. Radiology. 2020; 296 (3): E186–188. DOI: 10.1148/radiol.2020201544.Grillet F., Behr J., Calame P. et al. Acute pulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography. Radiology. 2020; 296 (3): E186–188. DOI: 10.1148/radiol.2020201544.Léonard-Lorant I., Delabranche X., Séverac F. et al. Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to D-dimer levels. Radiology. 2020; 296 (3): E189–191. DOI: 10.1148/radiol.2020201561.Léonard-Lorant I., Delabranche X., Séverac F. et al. Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to D-dimer levels. Radiology. 2020; 296 (3): E189–191. DOI: 10.1148/radiol.2020201561.Perez-Mies B., Gomez-Rojo M., Carretero-Barrio I. et al. Pulmonary vascular proliferation in patients with severe COVID-19: an autopsy study. Thorax. 2021; 76 (10): 1044–1046. DOI: 10.1136/thoraxjnl-2020-216714.Perez-Mies B., Gomez-Rojo M., Carretero-Barrio I. et al. Pulmonary vascular proliferation in patients with severe COVID-19: an autopsy study. Thorax. 2021; 76 (10): 1044–1046. DOI: 10.1136/thoraxjnl-2020-216714.Babapoor-Farrokhran S., Gill D., Walker J. et al. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020; 253: 117723. DOI: 10.1016/j.lfs.2020.117723.Babapoor-Farrokhran S., Gill D., Walker J. et al. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020; 253: 117723. DOI: 10.1016/j.lfs.2020.117723.Li S.S., Cheng C.W., Fu C.L. et al. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation. 2003; 108 (15): 1798–1803. DOI: 10.1161/01.CIR.0000094737.21775.32.Li S.S., Cheng C.W., Fu C.L. et al. Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. Circulation. 2003; 108 (15): 1798–1803. DOI: 10.1161/01.CIR.0000094737.21775.32.Yu C.M., Wong R.S., Wu E.B. et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad. Med. J. 2006; 82 (964): 140–144. DOI: 10.1136/pgmj.2005.037515.Yu C.M., Wong R.S., Wu E.B. et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad. Med. J. 2006; 82 (964): 140–144. DOI: 10.1136/pgmj.2005.037515.Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5.Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5.Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061–1069. DOI: 10.1001/jama.2020.1585.Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061–1069. DOI: 10.1001/jama.2020.1585.Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5 (7): 811–818. DOI: 10.1001/jamacardio.2020.1017.Guo T., Fan Y., Chen M. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5 (7): 811–818. DOI: 10.1001/jamacardio.2020.1017.Oudit G.Y., Kassiri Z., Jiang C. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Investig. 2009; 39 (7): 618–625. DOI: 10.1111/j.1365-2362.2009.02153.x.Oudit G.Y., Kassiri Z., Jiang C. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur. J. Clin. Investig. 2009; 39 (7): 618–625. DOI: 10.1111/j.1365-2362.2009.02153.x.Crackower M.A., Sarao R., Oudit G.Y. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417 (6891): 822–828. DOI: 10.1038/nature00786.Crackower M.A., Sarao R., Oudit G.Y. et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417 (6891): 822–828. DOI: 10.1038/nature00786.Oudit G.Y., Kassiri Z., Patel M.P. et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 2007; 75 (1): 29–39. DOI: 10.1016/j.cardiores.2007.04.007.Oudit G.Y., Kassiri Z., Patel M.P. et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 2007; 75 (1): 29–39. DOI: 10.1016/j.cardiores.2007.04.007.Zhao X., Nicholls J.M., Chen Y.G. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-β signaling. J. Biol. Chem. 2008; 283 (6): 3272–3280. DOI: 10.1074/jbc.M708033200.Zhao X., Nicholls J.M., Chen Y.G. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-β signaling. J. Biol. Chem. 2008; 283 (6): 3272–3280. DOI: 10.1074/jbc.M708033200.Cameron M.J., Ran L., Xu L. et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 2007; 81 (16): 8692–8706. DOI: 10.1128/JVI.00527-07.Cameron M.J., Ran L., Xu L. et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 2007; 81 (16): 8692–8706. DOI: 10.1128/JVI.00527-07.Cameron M.J., Bermejo-Martin J.F., Danesh A. et al. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008; 133 (1): 13–19. DOI: 10.1016/j.virusres.2007.02.014.Cameron M.J., Bermejo-Martin J.F., Danesh A. et al. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008; 133 (1): 13–19. DOI: 10.1016/j.virusres.2007.02.014.Wong C.K., Lam C.W., Wu A.K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004; 136 (1): 95–103. DOI: 10.1111/j.1365-2249.2004.02415.x.Wong C.K., Lam C.W., Wu A.K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin. Exp. Immunol. 2004; 136 (1): 95–103. DOI: 10.1111/j.1365-2249.2004.02415.x.Rizzo P., Vieceli Dalla Sega F., Fortini F. et al. COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm? Basic Res. Cardiol. 2020; 115 (3): 31. DOI: 10.1007/s00395-020-0791-5.Rizzo P., Vieceli Dalla Sega F., Fortini F. et al. COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm? Basic Res. Cardiol. 2020; 115 (3): 31. DOI: 10.1007/s00395-020-0791-5.Abbasi S.H., Boroumand M.A. Expanded network of inflammatory markers of atherogenesis: where are we now? Open Cardiovasc. Med. J. 2010; 4: 38–44. DOI: 10.2174/1874192401004020038.Abbasi S.H., Boroumand M.A. Expanded network of inflammatory markers of atherogenesis: where are we now? Open Cardiovasc. Med. J. 2010; 4: 38–44. DOI: 10.2174/1874192401004020038.Vonk Noordegraaf A., Westerhof B.E., Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension. J. Am. Coll Cardiol. 2017; 69 (2): 236–243. DOI: 10.1016/j.jacc.2016.10.047.Vonk Noordegraaf A., Westerhof B.E., Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension. J. Am. Coll Cardiol. 2017; 69 (2): 236–243. DOI: 10.1016/j.jacc.2016.10.047.García-Cruz E., Manzur-Sandoval D., Baeza-Herrera L.A. et al. Acute right ventricular failure in COVID-19 infection: a case series. J. Cardiol. Cases. 2021; 24 (1): 45–48. DOI: 10.1016/j.jccase.2021.01.001.García-Cruz E., Manzur-Sandoval D., Baeza-Herrera L.A. et al. Acute right ventricular failure in COVID-19 infection: a case series. J. Cardiol. Cases. 2021; 24 (1): 45–48. DOI: 10.1016/j.jccase.2021.01.001.Isgro G., Yusuff H.O., Zochios V., Protecting the right ventricle network. The right ventricle in COVID-19 lung injury: proposed mechanisms, management, and research gaps. J. Cardiothorac. Vasc. Anesth. 2021; 35 (6): 1568–1572. DOI: 10.4330/wjc.v15.i4.165.Isgro G., Yusuff H.O., Zochios V., Protecting the right ventricle network. The right ventricle in COVID-19 lung injury: proposed mechanisms, management, and research gaps. J. Cardiothorac. Vasc. Anesth. 2021; 35 (6): 1568–1572. DOI: 10.4330/wjc.v15.i4.165.Sanz J., Sánchez-Quintana D., Bossone E. et al. Anatomy, function, and dysfunction of the right ventricle: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019; 73 (12): 1463–1482. DOI: 10.1016/j.jacc.2018.12.076.Sanz J., Sánchez-Quintana D., Bossone E. et al. Anatomy, function, and dysfunction of the right ventricle: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019; 73 (12): 1463–1482. DOI: 10.1016/j.jacc.2018.12.076.Azevedo R.B., Botelho B.G., Hollanda J.V.G. et al. COVID-19 and the cardiovascular system: a comprehensive review. J. Hum. Hypertens. 2021; 35 (1): 4–11. DOI: 10.1038/s41371-020-0387-4.Azevedo R.B., Botelho B.G., Hollanda J.V.G. et al. COVID-19 and the cardiovascular system: a comprehensive review. J. Hum. Hypertens. 2021; 35 (1): 4–11. DOI: 10.1038/s41371-020-0387-4.Manzur-Sandoval D., García-Cruz E., Gopar-Nieto R. et al. Right ventricular dysfunction and right ventricular-arterial uncoupling at admission increase the in-hospital mortality in patients with COVID-19 disease. Echocardiography. 2021; 38 (8): 1345–1351. DOI: 10.1111/echo.15164.Manzur-Sandoval D., García-Cruz E., Gopar-Nieto R. et al. Right ventricular dysfunction and right ventricular-arterial uncoupling at admission increase the in-hospital mortality in patients with COVID-19 disease. Echocardiography. 2021; 38 (8): 1345–1351. DOI: 10.1111/echo.15164.Pagnesi M., Baldetti L., Beneduce А. et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020; 106 (17): 1324–1331. DOI: 10.1136/heartjnl-2020-317355.Pagnesi M., Baldetti L., Beneduce А. et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020; 106 (17): 1324–1331. DOI: 10.1136/heartjnl-2020-317355.Li Y., Li H., Zhu S. et al. Prognostic value of right ventricular longitudinal strain in patients with COVID-19. JACC Cardiovasc. Imaging. 2020; 13 (11): 2287–2299. DOI: 10.1016/j.jcmg.2020.04.014.Li Y., Li H., Zhu S. et al. Prognostic value of right ventricular longitudinal strain in patients with COVID-19. JACC Cardiovasc. Imaging. 2020; 13 (11): 2287–2299. DOI: 10.1016/j.jcmg.2020.04.014.Stockenhuber A., Vrettos А., Androschuck V. et al. A pilot study on right ventricular longitudinal strain as a predictor of outcome in COVID-19 patients with evidence of cardiac involvement. Echocardiography. 2021; 38 (2): 222–229. DOI: 10.1111/echo.14966.Stockenhuber A., Vrettos А., Androschuck V. et al. A pilot study on right ventricular longitudinal strain as a predictor of outcome in COVID-19 patients with evidence of cardiac involvement. Echocardiography. 2021; 38 (2): 222–229. DOI: 10.1111/echo.14966.Министерство здравоохранения Российской Федерации. Временные клинические рекомендации: Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 14 (27.12. 2021). Доступно на: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/041/original/%D0%92%D0%9C%D0%A0_COVID-19_V14_27-12-2021.pdfMinistry of Health of the Russian Federation. [The temporary guidelines: Prevention, diagnosis, and treatment of novel coronavirus infection (COVID-19)]. Version 14 (December 27, 2021). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/041/original/%D0%92%D0%9C%D0%A0_COVID-19_V14_27-12-2021.pdf (in Russian).Tsareva N.A., Avdeev S.N., Kosanovic D. et al. Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome. Crit. Care. 2021; 25 (1): 258. DOI: 10.1186/s13054-021-03690-7.Tsareva N.A., Avdeev S.N., Kosanovic D. et al. Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome. Crit. Care. 2021; 25 (1): 258. DOI: 10.1186/s13054-021-03690-7.Государственный реестр лекарственных средств. Инструкция по медицинскому применению лекарственного препарата Илопрост-Фармасинтез. Доступно на: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1015b019-4d56-42bb-a025-9a33574c1d3f [Дата обращения: 26.04.2023].State Register of Medicines. [Instructions for the medical use of the drug Iloprost-Pharmasynthesis]. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1015b019-4d56-42bb-a025-9a33574c1d3f [Accessed: April 26, 2023] (in Russian).

The authors declare that there are no conflicts of interest present.